Effects of cholecystokinin octapeptide on striatal dopamine metabolism and on apomorphine-induced stereotyped cage-climbing in mice

Research output: Contribution to journalArticle

74 Citations (Scopus)

Abstract

The effects of sulfated (CCK-8-SE) and non-sulfated (CCK-8-NS) cholecystokinin octapeptide on striatal dopamine (DA) metabolism have been investigated on mice. CCK-8-NS facilitated the disappearance of striatal DA, measured after synthesis inhibition with 350 mg/kg of α-methyl-p-tyrosine. CCK-8-SE, did not affect DA disapperance. In vitro uptake of [3H]DA by striatal slices was affected by neither CCK-8-SE, nor CCK-8-NS (10-5 M). Potassium-induced in vitro release of [3H]DA from striatal slices was significantly increased by 10-5 M CCK-8 NS: however, CCK-8-SE likewise increased DA release in this model system. Apomorphine-induced (1.0 mg/kg) stereotyped cage-climbing behavior was not affected by CCK-8-SE but was enhanced by CCK-8-NS. This effect could be antagonized by haloperidol, but not by naloxone. The data suggest that CCK-8-NS affects striatal DA release, disappearance and receptor sensitivity in the mouse. Dopaminergic mechanisms should therefore be regarded as a possible mode of action of CCK-8-NS on brain functions.

Original languageEnglish
Pages (from-to)313-319
Number of pages7
JournalEuropean Journal of Pharmacology
Volume69
Issue number3
DOIs
Publication statusPublished - Jan 29 1981

Fingerprint

Corpus Striatum
Sincalide
Apomorphine
Dopamine
Haloperidol
Naloxone
Tyrosine
Potassium

Keywords

  • Apomorphine
  • CCK-8
  • DA disappearance
  • DA release
  • DA uptake
  • Stereotyped behavior

ASJC Scopus subject areas

  • Cellular and Molecular Neuroscience
  • Pharmacology

Cite this

@article{6e8c507e966b4c65905d5749d3128c9b,
title = "Effects of cholecystokinin octapeptide on striatal dopamine metabolism and on apomorphine-induced stereotyped cage-climbing in mice",
abstract = "The effects of sulfated (CCK-8-SE) and non-sulfated (CCK-8-NS) cholecystokinin octapeptide on striatal dopamine (DA) metabolism have been investigated on mice. CCK-8-NS facilitated the disappearance of striatal DA, measured after synthesis inhibition with 350 mg/kg of α-methyl-p-tyrosine. CCK-8-SE, did not affect DA disapperance. In vitro uptake of [3H]DA by striatal slices was affected by neither CCK-8-SE, nor CCK-8-NS (10-5 M). Potassium-induced in vitro release of [3H]DA from striatal slices was significantly increased by 10-5 M CCK-8 NS: however, CCK-8-SE likewise increased DA release in this model system. Apomorphine-induced (1.0 mg/kg) stereotyped cage-climbing behavior was not affected by CCK-8-SE but was enhanced by CCK-8-NS. This effect could be antagonized by haloperidol, but not by naloxone. The data suggest that CCK-8-NS affects striatal DA release, disappearance and receptor sensitivity in the mouse. Dopaminergic mechanisms should therefore be regarded as a possible mode of action of CCK-8-NS on brain functions.",
keywords = "Apomorphine, CCK-8, DA disappearance, DA release, DA uptake, Stereotyped behavior",
author = "G. Kov{\'a}cs and Gyula Szab{\'o} and B. Penke and G. Telegdy",
year = "1981",
month = "1",
day = "29",
doi = "10.1016/0014-2999(81)90477-5",
language = "English",
volume = "69",
pages = "313--319",
journal = "European Journal of Pharmacology",
issn = "0014-2999",
publisher = "Elsevier",
number = "3",

}

TY - JOUR

T1 - Effects of cholecystokinin octapeptide on striatal dopamine metabolism and on apomorphine-induced stereotyped cage-climbing in mice

AU - Kovács, G.

AU - Szabó, Gyula

AU - Penke, B.

AU - Telegdy, G.

PY - 1981/1/29

Y1 - 1981/1/29

N2 - The effects of sulfated (CCK-8-SE) and non-sulfated (CCK-8-NS) cholecystokinin octapeptide on striatal dopamine (DA) metabolism have been investigated on mice. CCK-8-NS facilitated the disappearance of striatal DA, measured after synthesis inhibition with 350 mg/kg of α-methyl-p-tyrosine. CCK-8-SE, did not affect DA disapperance. In vitro uptake of [3H]DA by striatal slices was affected by neither CCK-8-SE, nor CCK-8-NS (10-5 M). Potassium-induced in vitro release of [3H]DA from striatal slices was significantly increased by 10-5 M CCK-8 NS: however, CCK-8-SE likewise increased DA release in this model system. Apomorphine-induced (1.0 mg/kg) stereotyped cage-climbing behavior was not affected by CCK-8-SE but was enhanced by CCK-8-NS. This effect could be antagonized by haloperidol, but not by naloxone. The data suggest that CCK-8-NS affects striatal DA release, disappearance and receptor sensitivity in the mouse. Dopaminergic mechanisms should therefore be regarded as a possible mode of action of CCK-8-NS on brain functions.

AB - The effects of sulfated (CCK-8-SE) and non-sulfated (CCK-8-NS) cholecystokinin octapeptide on striatal dopamine (DA) metabolism have been investigated on mice. CCK-8-NS facilitated the disappearance of striatal DA, measured after synthesis inhibition with 350 mg/kg of α-methyl-p-tyrosine. CCK-8-SE, did not affect DA disapperance. In vitro uptake of [3H]DA by striatal slices was affected by neither CCK-8-SE, nor CCK-8-NS (10-5 M). Potassium-induced in vitro release of [3H]DA from striatal slices was significantly increased by 10-5 M CCK-8 NS: however, CCK-8-SE likewise increased DA release in this model system. Apomorphine-induced (1.0 mg/kg) stereotyped cage-climbing behavior was not affected by CCK-8-SE but was enhanced by CCK-8-NS. This effect could be antagonized by haloperidol, but not by naloxone. The data suggest that CCK-8-NS affects striatal DA release, disappearance and receptor sensitivity in the mouse. Dopaminergic mechanisms should therefore be regarded as a possible mode of action of CCK-8-NS on brain functions.

KW - Apomorphine

KW - CCK-8

KW - DA disappearance

KW - DA release

KW - DA uptake

KW - Stereotyped behavior

UR - http://www.scopus.com/inward/record.url?scp=0019352208&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0019352208&partnerID=8YFLogxK

U2 - 10.1016/0014-2999(81)90477-5

DO - 10.1016/0014-2999(81)90477-5

M3 - Article

C2 - 6260512

AN - SCOPUS:0019352208

VL - 69

SP - 313

EP - 319

JO - European Journal of Pharmacology

JF - European Journal of Pharmacology

SN - 0014-2999

IS - 3

ER -